Clinical Trial Update: A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating safety, tolerability, and evidence of activity of the investigational drug FCFD4514S in geographic atrophy has been completed, with d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• FCFD4514S

Snippet

Sponsor: Genentech, Inc. | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED